Mylan Revenues And Revenue Growth From 2012 To 2016

This report provides the last five years revenues and revenue growth of Mylan N.V. (MYL) from 2012 to 2016. Mylan generated a total of $11.1 billion revenues during 2016. Mylan reported a revenue growth of 17.5% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Mylan Revenues From 2012 To 2016

Here are the revenues and the revenue growth details of Mylan during the last five years:

  • Mylan generated a total of $6.8 billion revenues during 2012. Mylan reported a revenue growth of 10.9% year-over-year during 2012.
  • Mylan generated a total of $6.9 billion revenues during 2013. Mylan reported a revenue growth of 1.7% year-over-year during 2013.
  • Mylan generated a total of $7.7 billion revenues during 2014. Mylan reported a revenue growth of 11.7% year-over-year during 2014.
  • Mylan generated a total of $9.4 billion revenues during 2015. Mylan reported a revenue growth of 22.1% year-over-year during 2015.
  • Mylan generated a total of $11.1 billion revenues during 2016. Mylan reported a revenue growth of 17.5% year-over-year during 2016.

Why Analyze Revenue Growth?

Revenue growth is the most commonly analyzed financial metric. Revenue Growth is the percent increase (or decrease) of a company's revenue between two time periods. It is computed by using the following formula: ((revenues during the time period two - revenues during the time period one) / revenues during the time period one)*100. If the time periods are two consecutive years, then the revenue growth is referred to as the annual revenue growth year-over-year. If the time periods are two consecutive quarters, then the revenue growth is referred to as the quarterly revenue growth quarter-over-quarter. If the time periods refer to the same quarter in the two consecutive years, then the revenue growth is referred to as quarterly revenue growth year-over-year. In case the time periods are two non-consecutive years, then the revenue CAGR (Commutative Annual Growth Rate) is computed.

Revenue growth analysis is important for a number of reasons. First, it helps in understanding how a business is performing. If the revenue growth rates are positive, it means the business is performing well and the revenues are increasing. If the revenue growth rates are negative, it means the revenues are declining and the company needs to take measures to increase them. If they don't, the company will continue to shrink. Second, a company's historical revenue growth analysis along with the market size and market share analysis helps in forecasting the future revenues of a company. Third, a comparison of a company's growth rates with its competitors helps in determining who is winning more business. A revenue growth higher than the industry average translates into increasing market share. Companies with very high revenue growth rates have the potential to be the industry disrupters.

Mylan Ranking

With $11.1 billion revenues, Mylan ranked number 263 in the R&P Research list of top-3000 public companies in the US by revenues during 2016. Each one of the top-3000 companies generated more than $50 million of annual revenues during 2016.

The top-20 companies in the US by revenues during 2016 were:

  1. Walmart ($482.1 billion)
  2. ExxonMobil ($226.1 billion)
  3. Berkshire Hathaway ($223.6 billion)
  4. Apple ($215.6 billion)
  5. McKesson ($190.9 billion)
  6. UnitedHealth Group ($184.8 billion)
  7. CVS Health ($177.5 billion)
  8. General Motors ($166.4 billion)
  9. AT&T ($163.8 billion)
  10. Ford Motor ($151.8 billion)
  11. AmerisourceBergen ($146.8 billion)
  12. Amazon ($136 billion)
  13. Verizon ($126 billion)
  14. General Electric ($123.7 billion)
  15. Cardinal Health ($121.5 billion)
  16. Costco ($118.7 billion)
  17. Walgreens Boots Alliance ($117.4 billion)
  18. Chevron ($114.5 billion)
  19. Kroger ($109.8 billion)
  20. Express Scripts Holding ($100.3 billion)

For the purpose of performance benchmarking of a company with a sector or industry average, R&P Research associates every company with one sector and one industry. An industry consists of companies with related/similar business models. A sector comprises of a group of related/similar industries. For high-level analysis purposes, related/similar sectors are grouped into sector groups.

For example, Healthcare sector group is comprised of Life Sciences sector and Healthcare Services sector. Life Sciences sector is comprised of following industries: Pharmaceuticals; Medical Devices; Biotechnology; Diagnostics & Scientific Instruments. Healthcare Services sector is comprised of following industries: Drug Stores, PBM and Distributors; Healthcare Payers; Healthcare Providers; Medical Software; Healthcare Research Services.

Mylan is associated with Healthcare Sector Group, Life Sciences Sector, and Pharmaceuticals Industry.

With $11.1 billion revenues, Mylan ranked number 38 of all the companies in the US Healthcare sector group. There were a total of 290 public companies in the US Healthcare sector group that had revenues greater than $50 million during 2016.

The top-10 companies in the US Healthcare sector group by revenues during 2016 were:

  1. McKesson ($190.9 billion)
  2. UnitedHealth Group ($184.8 billion)
  3. CVS Health ($177.5 billion)
  4. AmerisourceBergen ($146.8 billion)
  5. Cardinal Health ($121.5 billion)
  6. Walgreens Boots Alliance ($117.4 billion)
  7. Express Scripts Holding ($100.3 billion)
  8. Anthem ($84.9 billion)
  9. J&J ($71.9 billion)
  10. Aetna ($63.2 billion)

Healthcare sector group is comprised of the following sectors: Life Sciences; Healthcare Services.

With $11.1 billion revenues, Mylan ranked number 18 of all the companies in the US Life Sciences sector. There were a total of 197 public companies in the US Life Sciences sector that had revenues greater than $50 million during 2016.

The top-10 companies in the US Life Sciences sector by revenues during 2016 were:

  1. J&J ($71.9 billion)
  2. Pfizer ($52.8 billion)
  3. Merck ($39.8 billion)
  4. Gilead Sciences ($30.4 billion)
  5. Medtronic ($28.8 billion)
  6. Abbvie ($25.6 billion)
  7. Amgen ($23 billion)
  8. Eli Lilly ($21.2 billion)
  9. Abbott Laboratories ($20.9 billion)
  10. Bristol Myers Squibb ($19.4 billion)

Life Sciences sector is comprised of the following industries: Pharmaceuticals; Medical Devices; Biotechnology; Diagnostics & Scientific Instruments. The definitions for each of the industries is as follows:

  • Pharmaceuticals industry includes companies that discover, develop, manufacture, and market medicines licensed for use as medications. In general these companies offer pharmaceutical products that can be described as prescription or over-the-counter medicines. Many Pharmaceutical companies also offer a diverse portfolio of animal health products, services and solutions. Many diversified pharmaceutical companies operate in more than two operating segments like consumer health products, medical devices and pharmaceutical.
  • Medical Devices industry includes manufacturers and distributors of medical equipments and medical supplies. Medical equipments include large scale capital equipmets such as X-Ray machines and MRI scanners and other nondisposable medical devices like stents and pacemakers. Medical supplies include makers of contact lenses, eyeglass lenses, bandages and other disposable products.
  • Biotechnology industry includes Biotechnology product companies, subscription companies, and service companies. Biotechnology product companies offer pharmaceutical drug products that are manufactured in, extracted from, or semi synthesized from biological sources. Subscription-based companies develop genome databases, which can be used to develop medicinal drugs. Service companies offer solutions based on a common technology or generic tool of other large pharmaceutical or biopharmaceutical companies.
  • Diagnostics & Scientific Instruments industry includes companies that provide testing products, diagnostic reagents, instruments and diagnostic services to aid in the detection and treatment of a wide range of diseases. It also includes molecular diagnostic and genetic testing companies that develop, manufacture, market and provide diagnostic tests, diagnostic systems and related products and services. Also included are companies that manufacture and market analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics.

With $11.1 billion revenues, Mylan ranked number 9 of all the companies in the US Pharmaceuticals industry. There were a total of 49 public companies in the US Pharmaceuticals industry that had revenues greater than $50 million during 2016.

The top-10 companies in the US Pharmaceuticals industry by revenues during 2016 were:

  1. J&J ($71.9 billion)
  2. Pfizer ($52.8 billion)
  3. Merck ($39.8 billion)
  4. Eli Lilly ($21.2 billion)
  5. Abbott Laboratories ($20.9 billion)
  6. Bristol Myers Squibb ($19.4 billion)
  7. Allergan ($14.6 billion)
  8. Shire ($11.4 billion)
  9. Mylan ($11.1 billion)
  10. Valeant Pharmaceuticals ($9.7 billion)

Companies Segmentation

To identify and analyze high/low growth or most/least profitable similar-size companies in different sectors or industries, R&P research classifies all companies into different segments based upon their revenues, revenue growth, and net profit margins.

Based upon their annual revenues, the companies are classified into one of the following four segments:

  1. Mega companies, having revenues greater than $50 billion.
  2. Very Large companies, having revenues between $10 billion and $50 billion.
  3. Large companies, having revenues between $1 billion and $10 billion.
  4. Mid-size companies, having revenues between $50 million and $1 billion.

With $11.1 billion revenues, Mylan was in the Very Large companies revenue segment during 2016. There were a total of 239 companies in the Very Large companies revenue segment during 2016.

Based upon their annual revenue growth, the companies are classified into one of the following eight segments:

  1. Very High positive growth companies, having annual revenue growth greater than 50%.
  2. High positive growth companies, having annual revenue growth between 20% and 50%.
  3. Medium positive growth companies, having annual revenue growth between 5% and 20%.
  4. Low positive growth companies, having annual revenue growth between 0% and 5%.
  5. Low negative growth companies, having annual revenue growth between -5% and 0%.
  6. Medium negative growth companies, having annual revenue growth between -20% and -5%.
  7. High negative growth companies, having annual revenue growth between -50% and -20%.
  8. Very High negative growth companies, having annual revenue growth less than -50%.

With 17.5% revenue growth year-over-year, Mylan was in the Medium positive revenue growth segment during 2016. There were a total of 876 companies in the Medium positive revenue growth segment during 2016. Of the US top-3000 companies, 1985 (nearly two-third of the total) had positive revenue growth and 1015 (nearly one-third of the total) had negative revenue growth during 2016.

Based upon their annual net profit margin, the companies are classified into one of the following eight segments:

  1. Very High positive margin companies, having net profit margin greater than 50%.
  2. High positive margin companies, having net profit margin between 20% and 50%.
  3. Medium positive margin companies, having net profit margin between 5% and 20%.
  4. Low positive margin companies, having net profit margin between 0% and 5%.
  5. Low negative margin companies, having net profit margin between -5% and 0%.
  6. Medium negative margin companies, having net profit margin between -20% and -5%.
  7. High negative margin companies, having net profit margin between -50% and -20%.
  8. Very High negative margin companies, having net profit margin less than -50%.

With a net margin of 4.3%, Mylan was in the Low positive net profit margin segment during 2016. There were a total of 707 companies in the Low positive net profit margin segment during 2016. Of the US top-3000 companies, 2244 (nearly three-fourth of the total) had positive net profit margin and 756 (nearly one-fourth of the total) had negative net profit margin during 2016.

Company Business Summary

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; antiretroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures; and Dymista, which is used for the treatment of seasonal allergic rhinitis. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hatfield, the United Kingdom.

Data Source

The chart and the data on this page are sourced from the R&P Research Industry Intelligence Platform. The platform provides the key financial metrics for all the public companies in the United States. The platform empowers users to compare last five or 15 years financial data of a company with the other companies or the industry averages. This benchmarking exercise yields powerful insights that can drive better business decisions.


Industry Peers and Competitors of Mylan

Bristol Myers Squibb (BMY) Business Analysis – Analyze Historical Performance, Strategic...

Bristol Myers Squibb Co with $19 billion revenues in the year 2016 was the number 6 Pharmaceuticals company. Read this report to know the top competitors of Bristol Myers Squibb and identify growth and cost optimization opportunities of Bristol Myers Squibb

Allergan (AGN) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Allergan Plc with $15 billion revenues in the year 2016 was the number 7 Pharmaceuticals company. Read this report to know the top competitors of Allergan and identify growth and cost optimization opportunities of Allergan

Shire (SHPG) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Shire Plc with $11 billion revenues in the year 2016 was the number 8 Pharmaceuticals company. Read this report to know the top competitors of Shire and identify growth and cost optimization opportunities of Shire

Valeant Pharmaceuticals (VRX) Business Analysis – Analyze Historical Performance, Strategic Priorities,...

Valeant Pharmaceuticals International, Inc. with $10 billion revenues in the year 2016 was the number 10 Pharmaceuticals company. Read this report to know the top competitors of Valeant Pharmaceuticals and identify growth and cost optimization opportunities of Valeant Pharmaceuticals

Zoetis (ZTS) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Zoetis Inc. with $5 billion revenues in the year 2016 was the number 11 Pharmaceuticals company. Read this report to know the top competitors of Zoetis and identify growth and cost optimization opportunities of Zoetis

Endo International (ENDP) Business Analysis – Analyze Historical Performance, Strategic Priorities,...

Endo International Plc with $4 billion revenues in the year 2016 was the number 12 Pharmaceuticals company. Read this report to know the top competitors of Endo International and identify growth and cost optimization opportunities of Endo International

Revenues Analysis

Mylan (MYL) Revenues And Revenue Growth From 2012 To 2016

This report provides the last five years revenues and revenue growth of Mylan N.V. (MYL) from 2012 to 2016. Mylan generated a total of $11.1 billion revenues during 2016. Mylan reported a revenue growth of 17.5% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Mylan (MYL) Revenues And Revenue Growth From 2002 To 2016

This report provides the last fifteen years revenues and revenue growth of Mylan N.V. (MYL) from 2002 to 2016. Mylan generated a total of $11.1 billion revenues during 2016. Mylan reported a revenue growth of 17.5% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Mylan (MYL) Revenue Growth Comparison With Industry Growth From 2012 To...

This report provides a comparison of Mylan N.V. (MYL) revenue growth with Pharmaceuticals industry growth during the last five years from 2012 to 2016. Mylan reported a revenue growth of 17.5% year-over-year during 2016. The Pharmaceuticals industry growth was 7.7% year-over-year during 2016. Mylan growth was faster than the industry during 2016.

Profit Analysis

Mylan (MYL) Net Profit And Net Margin From 2012 To 2016

This report provides the last five years net profit and net margin of Mylan N.V. (MYL) from 2012 to 2016. Mylan reported a total net income of $480 million during 2016. Mylan generated a total of $11.1 billion revenues during 2016. Mylan net profit margin was 4.3% during 2016. The net profit and the net profit margin correspond to the fiscal year ending in December.

Mylan (MYL) Net Profit And Net Margin From 2002 To 2016

This report provides the last fifteen years net profit and net margin of Mylan N.V. (MYL) from 2002 to 2016. Mylan reported a total net income of $480 million during 2016. Mylan generated a total of $11.1 billion revenues during 2016. Mylan net profit margin was 4.3% during 2016. The net profit and the net profit margin correspond to the fiscal year ending in December.

Mylan (MYL) Net Profit Margin Comparison With Industry From 2012 To...

This report provides a comparison of Mylan N.V. (MYL) net profit margin with Pharmaceuticals industry net profit margin during the last five years from 2012 to 2016. Mylan reported a net profit margin of 4.3% during 2016. The Pharmaceuticals industry net profit margin was 15.8% during 2016. Mylan was less profitable than the industry during 2016.

Cost & Expenses Analysis

Mylan (MYL) Cost of Sales (COGS) Analysis From 2012 To 2016

This report provides the last five years cost of sales (COGS) analysis of Mylan N.V. (MYL) from 2012 to 2016. Mylan spent a total of $6.4 billion on COGS during 2016. Mylan generated a total of $11.1 billion revenues during 2016. As a percentage of revenues, Mylan spent 57.6% of its total revenues on COGS during 2016. The cost of sales (COGS) numbers are for the fiscal year ending in December.

Mylan (MYL) Research & Development (R&D) Spending Analysis From 2012 To...

This report provides the last five years research and development (R&D) expenses of Mylan N.V. (MYL) from 2012 to 2016. Mylan spent a total of $826.8 million on research and development (R&D) activities during 2016. Mylan generated a total of $11.1 billion revenues during 2016. As a percentage of revenues, Mylan spent 7.5% of its total revenues on R&D activities during 2016. The R&D spending numbers are for the fiscal year ending in December.

Mylan (MYL) Sales, Marketing, General & Administrative (SG&A) Spending Analysis From...

This report provides the last five years sales, marketing, general & administrative (SG&A) expenses of Mylan N.V. (MYL) from 2012 to 2016. Mylan spent a total of $2.5 billion on sales, marketing, general, and administrative (SG&A) activities during 2016. Mylan generated a total of $11.1 billion revenues during 2016. As a percentage of revenues, Mylan spent 22.5% of its total revenues on SG&A activities during 2016. The SG&A spending numbers are for the fiscal year ending in December.

Working Capital Analysis

Mylan (MYL) Inventory Spending Analysis From 2012 To 2016

This report provides the last five years inventory spending analysis of Mylan N.V. (MYL) from 2012 to 2016. Mylan invested a total of $2.5 billion on inventories during 2016. Mylan generated a total of $11.1 billion revenues during 2016. As a percentage of revenues, Mylan invested 22.2% of its total revenues on inventories during 2016. The inventory numbers are for the fiscal year ending in December.

Mylan (MYL) Accounts Receivable (A/R) Analysis From 2012 To 2016

This report provides the last five years Accounts Receivable (A/R) analysis of Mylan N.V. (MYL) from 2012 to 2016. Mylan invested a total of $3.3 billion on accounts receivable during 2016. Mylan generated a total of $11.1 billion revenues during 2016. As a percentage of revenues, Mylan invested 29.9% of its total revenues on accounts receivable during 2016. The accounts receivable numbers are for the fiscal year ending in December.

Mylan (MYL) Accounts Payable (A/P) Analysis From 2012 To 2016

This report provides the last five years Accounts Payable (A/P) analysis of Mylan N.V. (MYL) from 2012 to 2016. Mylan invested a total of $1.3 billion on accounts payable during 2016. Mylan generated a total of $11.1 billion revenues during 2016. As a percentage of revenues, Mylan invested 12.2% of its total revenues on accounts payable activities during 2016. The accounts payable numbers are for the fiscal year ending in December.

Asset Management Analysis

Mylan (MYL) Property, Plant & Equipment (PP&E) Investment Analysis From 2012...

This report provides the last five years property, plant & equipment (PP&E) investment analysis of Mylan N.V. (MYL) from 2012 to 2016. Mylan invested a total of $2.3 billion on property, plant & equipment (PP&E) activities during 2016. Mylan generated a total of $11.1 billion revenues during 2016. As a percentage of revenues, Mylan invested 21% of its total revenues on PP&E activities during 2016. The PP&E investment numbers are for the fiscal year ending in December.

Mylan (MYL) Intangible Assets Analysis From 2012 To 2016

This report provides the last five years Intangible assets analysis of Mylan N.V. (MYL) from 2012 to 2016. Mylan invested a total of $23.7 billion on Intangible assets during 2016. Mylan generated a total of $11.1 billion revenues during 2016. As a percentage of revenues, Mylan invested 213.8% of its total revenues on intangible assets during 2016. The Intangible asset numbers are for the fiscal year ending in December.

Got Questions?

Get in touch with us. We are happy to help!

Contact Us:


sales@revenuesandprofits.com